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“Two roads diverged in a wood, and I– 
I took the one less traveled by” 
– Robert Frost  
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POPULAR SCIENCE SUMMARY 
The heart is arguably our most beloved organ. It is essential for life, and keeps the blood 
pumping in our bodies so that life can be enjoyed – in the setting of a healthy heart. Heart 
disease is a major cause of death and suffering in the world. Heart disease is a broad term 
including diseases that affect the heart itself, as well as diseases that also affect the blood 
vessels, including high blood pressure. For someone diagnosed with heart disease, it may be of 
interest to know what the future holds. To answer such questions, we need to examine the heart. 
One way of doing this is by cracking the chest open and looking at the exposed heart. 
Fortunately, safer options exist, and are recommended.   
Before each heartbeat, an electrical impulse that can be described as a chain reaction of 
firework bursts spreads through the heart. This electrical impulse results in the heart squeezing 
together, flushing the blood from the heart out through the blood vessels to the rest of the body´s 
organs. The electrical impulses of the heart can be recorded with an electrocardiography (ECG) 
machine by placing electrodes on the surface of the chest. In healthy hearts, the electrical 
firework patterns look fairly similar, but in heart disease the firework pattern may change. The 
ECG is a fast, accessible, and commonly used tool for diagnosing heart disease. However, it 
does not perfectly detect heart disease in all sick patients. That is why this thesis evaluated and 
developed the use of advanced ECG methods, whereby the electrical impulses – the firework 
pattern – were analyzed in a more technically advanced way than is typically done in a 
conventional ECG. The results of this thesis show that when using advanced ECG, heart 
disease can be confirmed or dismissed more accurately than otherwise. 
To see beyond the heart’s fireworks and into the structure and function of the heart, the work 
in this thesis used magnetic resonance imaging (MRI). MRI shows how the heart is moving 
and pumping, and also provides information about the heart muscle that otherwise can only be 
detected by viewing tissue samples in a microscope. Thus, MRI provides information about 
the heart that is close to that which could be obtained by cracking the chest open. The research 
in this thesis used both advanced ECG and MRI to evaluate the heart. With these tools, this 
thesis has found improved ways of detecting and diagnosing heart disease in patients using 
ECG, and new ways of predicting the risk of the heart failing, or the risk of dying.  
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ABSTRACT 
The electrocardiogram (ECG) is a common diagnostic tool in cardiology thanks to its high 
accessibility and low cost. However, in several cardiovascular diagnoses, including left 
ventricular hypertrophy (LVH), current conventional ECG measures and criteria have a poor 
diagnostic performance. LVH is associated with hypertension and diabetes, but is often missed 
by the standard 12-lead ECG. LVH is typically diagnosed by non-invasive imaging methods. 
Cardiovascular magnetic resonance (CMR) is the gold standard for diagnosing LVH. 
Advanced-ECG (A-ECG) is a term used to describe a combination of advanced ECG analysis 
methods, and has been shown to be of diagnostic and prognostic utility. The aims of this thesis 
were to investigate the ability of A-ECG to diagnose LVH, using CMR as reference, as well as 
investigating the prognostic ability of A-ECG measures with regards to morbidity and 
mortality. 
We found that increased extracellular volume fraction by CMR reduces voltage measures of 
conventional ECG criteria for LVH, including the Sokolow-Lyon index and Cornell indices. 
This may explain the limited sensitivity of the ECG in detecting LVH. We further investigated 
different patterns of LVH based on the relation between increased mass and wall thickness, 
and found that the different patterns differ on their electrocardiographic manifestation by A-
ECG. Furthermore, A-ECG had a higher diagnostic performance compared to conventional 
ECG LVH criteria.  
The ECG detects electrical changes, while LVH represents a structural change. Therefore, the 
electrical changes associated with LVH may be better referred to as left ventricular electrical 
remodeling (LVER). LVER, defined as the A-ECG measure spatial QRS-T angle exceeding 
the upper limit of normal, was found to have a higher accuracy in diagnosing LVH compared 
to conventional ECG LVH criteria. We also found that patients with LVER have a worse 
prognosis compared to patients without LVER. Lastly, we optimized a score based on ECG 
and CMR measures, respectively, to predict morbidity and mortality, and found that ECG and 
CMR are both strong and independent predictors of events. 
In conclusion, conventional ECG criteria lack sensitivity in detecting LVH, which may be 
explained by increased extracellular volume fraction or different structural patterns in LVH. 
A-ECG has a higher diagnostic accuracy than conventional ECG criteria for LVH and is 
prognostic beyond CMR measures. Lastly, we suggest that LVER should be used when 
electrical changes in LVH are addressed.  
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1 RATIONALE 
The focus of this thesis is electrocardiographic (ECG) diagnosis of electrical changes in 
structural changes of the heart including left ventricular hypertrophy (LVH) as measured by 
cardiovascular magnetic resonance (CMR) imaging. The ECG records the electrical 
conduction of the heart, and in a healthy person the ECG recording follows a specific pattern, 
but the pattern can be altered in cardiovascular disease. 
Cardiovascular disease is as a major cause of morbidity and mortality in the world (1), and the 
ECG is one of the most commonly used diagnostic tools in cardiology owing to its accessibility 
and low cost. However, the ECG has a limited sensitivity and variable specificity in detecting 
disease (2). Advanced ECG (A-ECG) is a term used to describe a combination of advanced 
ECG analysis methods using digital signal processing, and statistically determined diagnostic 
scores based on large samples of imaging-verified health and disease. A-ECG parameters 
include derived vectorcardiographic (VCG) measures (3), QRS-wave and T-wave complexity 
measures obtained using singular value decomposition (4), heart rate and QT variability, high 
frequency components of the QRS, and other published methodologies. A-ECG has been 
shown to be more sensitive, as well as more specific, at identifying a number of cardiac diseases 
compared to conventional ECG (4). Thus, there are compelling reasons to reassess the role of 
the ECG in detecting cardiac electrical remodeling and related abnormalities. Recent 
developments in state-of-the-art CMR have made it possible to accurately perform quantitative 
characterization of myocardial tissue properties such as myocardial scarring, diffuse 
myocardial fibrosis, edema, ventricular mass and function, and quantitative perfusion at rest 
and during pharmacological stress. These recent developments make CMR an excellent non-
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2 INTRODUCTION 
2.1 CARDIOVASCULAR DISEASE 
Cardiovascular disease is a term that includes diseases of the heart, peripheral vessels, and 
brain. It is the leading cause of morbidity and mortality in the world (1, 5), and is a hindrance 
for sustainable human development (6). Cardiovascular disease typically affects people in the 
middle of their lives, and the costs comprise an increasing burden on society (6). Major risk 
factors for cardiovascular disease are hypertension, obesity, diabetes mellitus, high blood 
cholesterol, smoking, and physical inactivity (7-10).  
2.1.1 Heart failure 
In a healthy person, the heart pumps enough blood to meet the oxygen and metabolic demand 
of the body. Heart failure (HF) is a condition in where there is an inability of the heart to provide 
adequate blood supply in relation to demand, while preserving normal filling pressure. HF is a 
common disease worldwide, with an increased incidence and prevalence in the aging 
population. In developed countries, HF has an overall prevalence of 2%, and is more common 
with increasing age and reaches a prevalence of 10% at 85 years of age (11). The prevalence 
of HF is thus expected to increase in countries with an aging population (12). The mortality in 
HF is high, but can be reduced with correct diagnosis, management and treatment. HF often 
progresses slowly as a chronic condition but can also be acute. The diagnosis of HF can be 
demanding as many patients may have other diseases that mimic or disguise HF. Symptoms of 
HF are related to the lack of adequate oxygen supply and/or the retention of fluids due to the 
impaired cardiac function. Clinical hallmark signs include shortness of breath, crackles upon 
lung auscultation, and swelling of the legs, neck veins and/or abdomen. Besides clinical signs, 
laboratory tests and imaging can help the clinician diagnose HF or its many causes. The most 
utilized laboratory test is the blood level of brain natriuretic peptide (BNP) which increases as 
a result of an increased stretching in cardiac muscle tissue, due to e.g. volume overload (13). A 
wide range of imaging and functional tests are used including ECG, echocardiography, nuclear 
imaging, computed tomography, and CMR, with or without pharmacological or exercise stress, 
and invasive cardiac catheterization.   
Heart failure has many causes, all of which impair the ability of the heart to efficiently pump 
blood, and can broadly be divided into ischemic, valvular, hypertensive, cardiomyopathic, 
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other, and unknown causes (14). Depending on symptoms, and level of physical activity, the 
New York Heart Association (NYHA) functional classification is typically used to define five 
stages of HF (15). According to the European Society of Cardiology Heart Failure Guidelines 
2016 HF can also be divided into HF with preserved left ventricular ejection fraction (LVEF) 
of ≥50%, HF with mid-range LVEF of 40–49%, or HF with reduced LVEF of <40% (16). 
2.1.2 Left ventricular hypertrophy 
Left ventricular hypertrophy (LVH) is a cardiac condition defined as an increased left 
ventricular (LV) mass (LVM) (2). Hypertrophy refers to an increase in the volume of a cell, 
leading to enlarged tissues or organs. Hypertrophy is distinguished from hyperplasia in which 
the cells increase in amount, also leading to enlarged tissues or organs. Besides enlarged 
cardiomyocytes, the hypertrophic myocardium also undergoes complex interstitial changes 
such as an accumulation of focal or diffuse myocardial fibrosis, inflammation, fatty infiltration, 
edema, or ischemic changes (2). The increased LV mass can lead to an imbalance in the 
myocardial blood supply, and an abnormal reorganization of myocardial composition (17). 
This can cause HF due to mechanical, vasomotor, and electrical dysfunction (18-21). LVH is 
associated with an increased incidence of cardiovascular disease including HF, stroke, and 
coronary heart disease (22), all leading contributors to decreased quality-of-life, 
hospitalization, and death in developed countries (23). LVH is typically diagnosed by cardiac 
imaging including echocardiography and CMR, or by ECG. Importantly, echocardiographic 
findings of LVH, and LVH by ECG correlate poorly, but both provide independent prediction 
of mortality and morbidity (24). This suggests that the ECG provides information about LVH 
beyond the increase in LV mass per se. 
LVH is defined as an increased LVM, but depending on the relation between mass and LV end 
diastolic volume (LVEDV), LVH can be subdivided into three different patterns (25): 1) 
concentric remodeling, defined as a normal LV mass with an increased wall thickness; 2) 
eccentric hypertrophy, defined as an increased LV mass with a normal wall thickness; and 3) 
concentric hypertrophy, defined as an increase in LV mass with an increased wall thickness. 
Global wall thickness (GT) has together with LVM been shown to accurately classify LVH 




  15 
Figure 2.1. Classification of LVH based on left ventricular mass and wall thickness 
 
Figure 2.1: Cardiovascular magnetic resonance images of four different hearts in a short-axis 
view. The four examples illustrate how normal and increased left ventricular mass index 
(LVMI) and left ventricular global wall thickness index (GTI) can classify left ventricular 
hypertrophy into three patterns: concentric remodeling, i.e. a normal LVMI and increased GTI 
(top left), eccentric hypertrophy i.e. an increased LVMI and normal GTI (bottom right), and 
concentric hypertrophy i.e.  both an increase in LVMI and GTI (top right). Cut-offs for normal 
and increased (not explicitly shown) are the sex-specific 95% upper limit of normal in healthy 
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Figure 2.2. Classification of LVH based on left ventricular mass and wall thickness 
 
Figure 2.2: A schematic figure of how normal and increased left ventricular (LV) mass index 
and LV global wall thickness index can classify left ventricular hypertrophy into three patterns: 
concentric remodeling, eccentric hypertrophy, and concentric hypertrophy. Cut-offs for 
normal and increased (not explicitly shown) are the sex-specific 95% upper limit of normal in 
healthy volunteers (26). The blue circles illustrate roughly how different patient groups are 
classified according to the schematic figure. The following patient groups are included: healthy 
volunteers, patients with recent acute ST-elevation myocardial infarction (Infarction),  
endurance athletes (Athletes), cardiac resynchronization therapy (CRT) candidates, patients 
with the genetic disorder Fabry disease (Fabry), and patients with at least moderate left 
ventricular hypertrophy (LVH). Figure adapted from Lundin, et al (27). 
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2.1.3 Left ventricular hypertrophy and diffuse myocardial fibrosis 
Fibrosis is a global health problem and present in nearly all forms of cardiovascular disease 
(28). It is a common final end point and is associated with impaired LV function, symptoms, 
and adverse prognosis. It has previously only been quantified by biopsy and histology, and as 
a result, it is not fully understood. CMR studies show that hypertrophic myocardium may 
include diffuse myocardial fibrosis and/or focal myocardial fibrosis (29). Diffuse myocardial 
fibrosis is a global abnormal accumulation of extracellular matrix in the myocardium  (17), 
whereas focal fibrosis, also known as scar, is focal and can be a result of myocardial infarction 
(MI) or other non-ischemic injuries such as myocarditis (30). The presence of these may 
influence the ECG interpretation of LVH (29). In the absence of amyloidosis, a disease 
characterized by an abnormal accumulation of proteins in tissue, or in the absence of 
myocardial edema, the primary interstitial component leading to an expansion in the 
extracellular matrix is myocardial collagen (18).  
In response to stress or injury, cardiac fibroblasts proliferate and differentiate into 
myofibroblasts. These cells secrete fibronectin, collagen I, and collagen III, which form 
extracellular matrix and fibrosis (29). Myofibroblasts also express pro-fibrotic and pro-
inflammatory factors that contribute to fibroblast proliferation and inflammation (28). This can 
lead to HF (17) due to mechanical, electrical or vasomotor dysfunction (29). An increase in 
myocardial fibrosis is a part of normal ageing (29), however, it progresses faster in diseases 
such as hypertension, diabetes mellitus, aortic stenosis, and hypertrophic cardiomyopathy. 
Furthermore, myocardial fibrosis is an independent contributor to mortality and morbidity, and 
the amount of fibrosis is directly correlated with arrhythmias and sudden cardiac arrest (29), as 
well as to hospitalization for heart failure and death (31). In comparison to focal fibrosis, diffuse 
myocardial fibrosis may be reversible and is a target of pharmacotherapy, e.g. targeting the 
renin-angiotensin-aldosterone system as it has an impact on the excessive accumulation of 
collagen I and III in myocardial extracellular matrix (32),  or a target of immunotherapy (33). 
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Figure 2.3. Histological analysis of myocardial tissue 
 
Figure 2.3: The myocardial tissue samples A, B, and C were embedded in paraffin. Picrosirius 
red was used to stain collagen (fibrosis) red/pink, and to stain myocytes yellow.  The samples 
demonstrate a A) 8%, B) 16%, and C) 36% collagen volume fraction, forming the extracellular 
volume. Figure reproduced from Miller, et al (34), with permission. 
2.2 ELECTRICAL CONDUCTION SYSTEM OF THE HEART 
Like many other cells in the body, cardiomyocytes can generate electrical potential. This occurs 
by a coordinated opening of voltage-gated channels with a selective permeability for sodium 
ion (Na+), potassium ion (K+), and calcium ion (Ca2+) channels, respectively. These are located 
in the lipid bilayer cell membrane, leading to a rapid change in voltage across the membrane. 
At rest, the concentration of potassium is relatively high inside the cell, and the sodium 
concentration is high outside of the cell. The normal resting membrane potential of a 
cardiomyocyte is -90 mV, which approximately corresponds to the equilibrium of K+. The 
action potential starts with a rapid inflowing current of Na+ and Ca2+ ions, whereby the cell 
depolarizes and the membrane potential increases and becomes positive (35). The action 
potential triggers different intracellular processes including contraction of the cell. The 
cardiomyocytes are connected through gap junctions (36), which are essentially non-selective 
channels through which the ions can flow cell-to-cell downstream, and a wave-like spread of 
action potentials is generated, leading to a synchronous contraction of the cardiomyocytes. 
After the depolarization, the intracellular K+ ions flow out of the cell leading to repolarization, 
and the cell returns to its negative resting membrane potential (35). Gap junctions are important 
for the rapid spread of the action potential. When the action potential has terminated, sodium-
calcium and sodium-potassium pumps located in the cell membrane restore the concentration 
of ions, and a new action protentional can start over.   
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Figure 2.4. Myocardial action potential and the ECG 
 
Figure 2.4: The temporal relation between the A) surface ECG, where the P-wave indicates 
the atrial depolarization, the QRS-wave the ventricular depolarization, and the T-wave the 
ventricular repolarization, B) the cardiomyocyte action potential with the depolarization and 
repolarization phases, and C) the inward depolarizing currents of Na+ and Ca2+, and the 
outward repolarizing currents of K+. Figure reproduced from George (37), with permission. 
Pacemaker cells are specialized cardiomyocytes with an ability to spontaneously initiate an 
action potential (38), and they form the electrical conduction system of the heart. In a healthy 
heart, pacemaker cells in the sino-atrial (SA) node, located in the roof of the right atrium (39) 
as shown in Figure 2.5, start each heartbeat. An electrical signal impulse begins to depolarize 
the atrial myocardial cells which leads to the atrial contraction. The electrical impulse then 
reaches the atrioventricular (AV) node, located in the right atrial floor, where the signal is 
delayed. After this, the electrical signal passes His’ bundle, through the ventricular septum, and 
into the left and right bundle branches. The right bundle branch divides into a delicate network 
called Purkinje fibers in the right ventricle that depolarize myocytes. The left bundle branch 
divides into an anterior and a posterior fascicle which subsequently divide into fine Purkinje 
fibers, and depolarize the ventricular myocardial cells.  
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Figure 2.5. Electrical conduction system of the heart 
 
 
Figure 2.5: The main components of the electrical conduction system of the heart: 1) sinoatrial 
node, 2) atrioventricular node, 3) bundle of His, 4) left bundle branch, 5) left-posterior fascicle, 
6) left-anterior fascicle, 7) left ventricle, 8) ventricular septum, 9) right bundle branch, and 10) 
right ventricle. Figure reproduced under a creative commons license. Original heart by 
illustrator Patrick Lynch and cardiologist Carl Jaffe, and electrical conduction system by J. 
Heuser.  
In cardiovascular disease, the electrical propagation and the heart rhythm may vary, which can 
be diagnosed by ECG. The electrical changes do not necessarily follow anatomical or structural 
changes of the heart (40), but are part of a complex process referred to as electrical remodeling 
(41). Previous studies show that changes in cardiac action potential are critical in the early 
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2.3 ELECTROCARDIOLOGY 
2.3.1 Electrocardiography 
As cardiology became a distinct medical specialty, various diagnostic techniques emerged and 
developed. The first human electrocardiographic recording was introduced more than a century 
ago by Augustus Waller in 1887 (45). However, the first clinically useful electrocardiogram 
was recorded by Willem Einthoven following his invention of the string galvanometer in 1901. 
The ECG signal was obtained from a patient by placing two extremities in saline solution, 
which led the electrical impulses from the heart to the electrocardiograph. 
In modern times, the ECG signal is obtained through skin electrodes placed on the body that 
capture the electrical activity of the depolarization and repolarization of the heart. The signal 
in the conventional 12-lead ECG is derived from ten electrodes places on the skin; one 
electrode on each limb including a ground (limb leads), and six electrodes on the torso 
(precordial or chest leads). The six precordial leads, called V1-V6, are placed at the level of the 
heart as standardized in 1938. The limb leads are placed on the right arm, left arm, and left foot, 
according to the convention proposed by Einthoven, creating the three limb leads (46). An 
additional limb electrode placed on the right foot serves as a ground. Einthoven assigned the 
letter P, Q, R, S, and T to the deflections of the ECG waveform. Initially, the waveforms were 
named the letters A, B, C, and D, but after major adaptions of the ECG, the letters were changed 
to the second half of the alphabet to denote an updated ECG system (47). He also described 
ECG features of various cardiovascular disorders. In 1924, Einthoven was awarded the Nobel 
Prize in Medicine for his work (48). Since then, the electrocardiograph has gone through 
different advancements, and can now have the size of a watch or smaller, and the ECG can be 
sent wirelessly to a computer for digital analysis. 
History of Advanced ECG 
A-ECG is a combination of more advanced ECG techniques based on a digital 10-second ECG 
recording, or longer (5 minutes), and often sampled at a higher frequency than the conventional 
ECG. The A-ECG techniques include conventional ECG parameters, vectorcardiography, QRS 
complex and T wave complexity, high frequency QRS wave and late potentials, P wave 
analysis, and beat-to-beat RR- and QT-variability A-ECG is also known as Space-EKG as the 
A-ECG software was developed at the National Aeronautics and Space Administration 
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(NASA) Johnson Space Center, Texas, USA, to better detect and prevent cardiovascular 
disease in astronauts.  
Figure 2.6. ECG lead placement and ECG waves 
 
Figure 2.6:  Upper panel. The standard ECG leads constitute of six extremity leads and six 
precordial leads. The extremity leads (aVL, I, -aVR, II, aVF, III) are placed on the limbs and 
record the voltage difference in the frontal plane. The precordial leads (V1-V6) are placed on 
the chest wall and record the voltage difference in the horizontal plane. The P wave and QRS 
complex display the atrial and ventricular depolarization, respectively, and the T wave displays 
the ventricular repolarization. Along the vertical direction of the ECG leads, wave amplitudes 
are measured, and along the horizontal direction heart rate and wave durations are measured. 
Figure adapted from Koelsch, et al (49), with permission. Lower panel. A normal conventional 
12-lead ECG with limb and precordial leads. The limb leads are displayed in the order of the 
Cabrera sequence (aVL, I, -aVR, II, aVF, III), as originally presented by Fumagalli (50). The 
Cabrera sequence is commonly used in Europe including in Sweden. 
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2.3.2 Vectorcardiography 
In 1920, Hubert Mann described the “monogram” (51), which later on was called the 
vectorcardiogram (VCG). While a standard 12-lead ECG references the sum of the electrical-
potential vectors from de- and repolarized cardiomyocytes to a scalar, one-dimensional plane, 
the VCG displays the vectors as a loop in the three-dimensional space. Three perpendicular 
two-dimensional planes; the frontal, horizontal, and (left) sagittal plane, illustrate the three-
dimensional spatial direction and magnitude of the vectors of the heart’s electrical activity (52). 
The VCG is useful due to its visual representation of the electrical activity and its spatial 
variation during the cardiac cycle (53). Initially, the VCG was constructed from a 3-lead ECG 
with the electrodes placed in the frontal plane of the torso in a modified Einthoven triangle. A 
VCG can also be derived from a standard 12-lead ECG using the Kors’ transform, a 
mathematical matrix validated using simultaneously recorded 12-lead ECGs and VCGs (3, 54), 
or using the inverse Dower matrix (55). For a number of reasons likely related to a combination 
of technical, interpretation-related, and acquisition standardization-related complexities, the 
VCG was effectively abandoned as a widely used clinical tool in the latter half of the twentieth 
century (56). However, recent developments, and computational resources in modern 
electrocardiographs, make it easier to obtain, display and interpret derived VCGs today. 
The VCG shows the magnitude and angular direction of the electrical activity at each time 
frame in the cardiac cycle. The QRS-T angle is an established VCG measure defined as the 
angle in three-dimensional space between the peak magnitude of the QRS and T loop vectors, 
respectively.  It has historically been measured by VCG using dedicated lead placement, but 
can now be derived from a standard 12-lead ECG. Similarly to the concordance or discordance 
of the QRS wave and T wave in a given lead in the conventional ECG, the QRS-T angle reflects 
the dispersion between the ventricular depolarization and repolarization (57). In a healthy heart, 
the angle is small, but it increases as a result of myocardial disease process (58) including in 
LVH (Study III), hypertension (59), diabetes (60), and hemophilia A (61). The QRS-T angle is 
also an independent predictor of cardiovascular mortality (62). 
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 Figure 2.7. Vectorcardiogram and the QRS-T angle
 
Figure 2.7: The vectorcardiogram (VCG) is useful as it visualizes the cardiac action potential 
in the three-dimensional space. The blue arrows show the ventricular net depolarization 
vectors’ magnitude and direction for each time frame. When the tips of the vectors are 
connected by the blue line, they form what is called the QRS loop. The same is applied for the 
T loop, but it represents the repolarization of the ventricle. A. A schematic illustration of the 
VCG measure spatial QRS-T angle, which is the angle between the largest vector in the QRS 
loop and T loop, respectively. B. An increased spatial QRS-T angle, which can be encountered 
in e.g. left ventricular hypertrophy. Figure modified from Study III. 
Besides three-dimensional VCG measures, polarcardiographic measures can also be derived 
from the 12-lead ECG. In addition to the VCG, which plots the direction and the magnitude of 
the heart’s electrical vector, the polarcardiogram also plots it over time, and in a spherical/polar 
coordinate system (63). The polar vector, which is illustrated in a polarcardiogram, has 
previously been shown to deviate in the setting of LVH in comparison to healthy subjects (64).  
 
2.3.3 QRS wave and T wave complexity 
Detailed studies of ECG waveforms can be obtained through singular value decomposition 
(SVD) performed on a conventional 12-lead ECG. SVD is a mathematical signal processing 
technique, whereby the depolarizing QRS-waves and repolarizing T-waves can be spatially 
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characterized in terms of orthogonal bases. The orthogonal bases, also referred to as 
eigenvectors or eigenvalues, are the vectors that span a room in a certain dimension, as 
illustrated in Figure 2.8. The magnitude of the eigenvectors represents the “energy” present in 
the respective wave. The eigenvectors are typically measured in microvolts, and two or more 
eigenvectors can be combined with each other to create sums and/or ratios of eigenvectors. 
Figure 2.8. Eigenvectors 
 
Figure 2.8: Eigenvectors illustrated in the three-dimensional space of an ellipse. The first base, 
or eigenvector, is the largest vector in the ellipse, Eigenvector 1. The second eigenvector is the 
second largest vector in the ellipse, Eigenvector 2, and is orthogonal to Eigenvector 1. The 
third eigenvector is the third largest vector, Eigenvector 3, and is orthogonal to Eigenvector 1 
and Eigenvector 2, respectively. Together the three eigenvectors span the room of the three-
dimensional ellipse. 
The standard 12-lead ECG is constructed from ten electrodes and eight unique channels: lead 
I, lead II, and lead V1 – V6. The remaining extremity leads can be derived from lead I and lead 
II. The eight unique channels represent eight dimensions of the electrical propagation. Thus, 
eight different eigenvectors for the (eight-dimensional) P loop, QRS loop and T loop, 
respectively, can be calculated.   
In a healthy heart, the first eigenvector in a de- or repolarization loop accounts for most of the 
energy that is present (65). In a homogeneous de- and repolarization there is also a presence of 
substantial energy in the second and third eigenvectors, and the energy decreases drastically as 
the eigenvectors increase. In cardiac disease, the energy may shift and become substantial even 
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in higher eigenvectors. Quantification of the magnitude of the respective eigenvectors has been 
shown to be diagnostically useful in cardiovascular disease (4, 66, 67). 
2.3.4 Left ventricular hypertrophy by electrocardiography 
ECG criteria for LVH were originally established from autopsies of enlarged ventricles or 
clinical features of the patients (68). Later, new imaging modalities, such as 2- and 3-
dimensional echocardiography and CMR, were adopted as the reference standard for 
determining the presence and severity of LVH. Such modalities became the reference standard 
for the ECG changes associated with LVH (68). LVH by ECG is typically assessed by various 
criteria. A total of 37 different criteria for LVH by ECG are recommended by the American 
Heart Association (2), but the Sokolow-Lyon voltage index, Romhilt-Estes criteria, and Cornell 
voltage and voltage product, respectively, are commonly used. In 1940 Sokolow and Lyon 
introduced a set of ECG criteria based on the sum of the R wave in lead V5 (RV5) or RV6 and 
Sv1 (sum >3.5 mV) (69). Today, the Sokolow-Lyon index is widely recognized clinically for 
diagnosing LVH. The Cornell voltage is the sum of RaVL and SV3 voltage (sum >2.0 mV for 
women and >2.8 mV for men) (70). More recently, several criteria have been added, making 
the clinical ECG diagnosis of LVH more complex (68). 
Figure 2.9. Electrocardiographic LVH 
 
Figure 2.9: High QRS-amplitudes on the ECG can be present in left ventricular hypertrophy. 
The combined amplitudes of the S-wave in lead V1, and the R-wave in lead V5 or V6, are 
increased in left ventricular hypertrophy, according to the Sokolow-Lyon voltage index. 
The diagnostic performance of the conventional ECG LVH criteria vary greatly, with a 
sensitivity typically around 50%, and a specificity typically approaching 90% (68). Because of 
this, a patient who is positive by one criterion is often negative by another criteria (68). A large 
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study identified patients (n=9194) with mild or severe hypertension, and either a positive 
Sokolow-Lyon index or Cornell voltage, were enrolled in a pre-enrollment screening (71). 
However, only 11.2% of the patients met both sets of criteria. In addition, different clinical 
characteristics and baseline demographics were associated with the two sets of criteria (71). 
Furthermore, varying sensitivity has also been reported in patients with different underlying 
cardiac disease (72). Regardless of the poor sensitivity and varying specificity of the 
conventional ECG criteria for detecting LVH, they may be used to predict all-cause mortality 
(73).  
Conventional ECG LVH criteria typically have a low sensitivity and varying specificity in 
detecting LVH, defined as an increased LV mass (74). LVH criteria by ECG are typically based 
on increased QRS complex amplitudes and prolonged durations, deviations in the ST-T 
regions, and electrical axis deviations. However, these measures and criteria are not always 
proportional to increased LV mass (2). The ECG reflects the generated electric activity which 
does not exclusively depend on increased mass (75). 
2.3.5 Left ventricular electrical remodeling 
Electrocardiographic LVH by conventional criteria is a misleading term as the ECG detects 
electrical changes in the heart while LVH is an anatomical and structural change, and 
anatomical and electrical changes are two different phenomena. Furthermore, the ECG has 
repeatably been shown to lack diagnostic accuracy whereas cardiovascular imaging is more 
accurate. The classical conceptual ECG LVH model, that heart disease leads to chamber 
enlargement, which leads to increases in QRS amplitudes and durations, is greatly simplified 
(40). It is based on a theoretical model of “ideal” LV hypertrophy, i.e. that the hypertrophy is 
symmetrical and diffuse, and that the electrical activation is unchanged, and this is how clinical 
cases are conventionally explained (76). Computer simulations of electrical propagation in 
different types of hypertrophy show that, depending on the arrangement of the hypertrophic 
cardiomyocytes, the ECG model of “ideal” hypertrophy results in increased QRS vectors (77). 
However, the more accurate in vivo scenario is much more complex with structural, 
bioelectrical and biochemical changes that interact and lead to mechanical, 
electrocardiographic, and rhythm effects. Furthermore, the tissue surrounding the heart, and 
body fat varies greatly among individuals, and also affect the electrical recordings.  
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Electrical remodeling is a term that includes the complex active and passive electrical 
properties of the myocardium. Electrical and structural remodeling are continuous processes 
and start in the early stages of cardiac pathology, and it is likely that electrical changes are 
manifested on the ECG before arrhythmias (78). Furthermore, LVH and structural heart disease 
include microscopic structural changes, and changes in metabolism, gap junctions, ion 
channels, and in the gene expression, all of which are substrates for triggering and maintaining 
arrhythmias (79-82).  
Figure 2.10. Classical and extended models of ECG diagnosis of LVH 
 
Figure 2.10: Conceptual models of electrocardiographic diagnosis of left ventricular 
hypertrophy. A. The “classical” conceptual model that heart disease leads to chamber 
enlargement and subsequent ECG abnormalities. B. An extended conceptual model for ECG 
diagnosis of left ventricular hypertrophy, as proposed by the Journal of Electrocardiology LVH 
Working Group. Figure A and B reproduced from Bacharova, et al (40), with permission.  
The Journal of Electrocardiography LVH working group (40) has previously proposed that the 
term left ventricular electrical remodeling (LVER) should be used when describing the 
electrical changes associated with LVH. However, the definition and criteria for LVER were 
not proposed. Therefore, one of the main aims of Study III was to define ECG criteria for 
LVER.  
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2.4 CARDIOVASCULAR MAGNETIC RESONANCE IMAGING 
Cardiovascular imaging can be accomplished using various techniques including CMR, 
echocardiography, single photon emission tomography (SPECT), positron emission 
tomography (PET), and x-ray computed tomography (CT). CMR was introduced as a clinical 
tool in the early 1980s, and through various developments and applications it is now the 
reference standard for evaluating cardiac function, structure (83), viability, and myocardial 
perfusion (84). It is used to assess myocardial ischemia, cardiomyopathies, myocardial 
interstitial disease, congenital heart disease, and myocardial inflammation, among other 
conditions. CMR is relatively expensive and less readily available compared to 
echocardiography, but when operated by experienced operators, CMR has a high diagnostic 
accuracy, and is associated with few risks. In comparison to CT and SPECT, CMR exams can 
be performed repeatedly without requiring exposure to ionizing radiation. Also, a gadolinium-
based contrast agent is often administrated intravenously as a part of the CMR exam, and 
adverse reactions including anaphylaxis are exceedingly rare (<1 in 10,000 cases) (85).  
Generating images using MRI scanners is a complex physical and technical procedure. Briefly, 
radio waves, strong magnetic fields, and magnetic field gradients are utilized to image the body 
and visualize different tissue properties (86). Clinical CMR is generally performed using 1.5 
tesla (T) or 3.0 T magnets. The signal in the images is derived from hydrogen atoms, which are 
abundant in the human body. When a patient is inside the scanner and exposed to the strong 
magnetic field, the protons in the hydrogen nuclei align in the magnetic field. By exciting the 
nuclei with a radio frequency pulse, a signal is obtained through a resonance phenomenon (87). 
By varying the magnitude, spatial directions, and timing of the radio frequency pulses and the 
magnetic field gradients, the MRI scanner is capable of producing high-resolution images that 
reflect different properties of the tissue, such as proton density or relaxation properties, denoted 
by the time constants T1 and T2 (88).  
2.4.1 Extracellular volume fraction 
T1 measurement by CMR involves measurement of the time constant of relaxation, or the 
recovery, of the proton orientation in relation to its original position in the magnetic field after 
being excited by a radio frequency pulse. T1 maps by CMR provide quantitative myocardial 
tissue characterization with a high signal-to-noise ratio (23). T1 mapping before and after 
intravenous administration of a gadolinium-based contrast agent can be used to measure the 
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size of the myocardial extracellular space. The contrast agent is small enough to distribute 
freely in the extracellular space, but large enough that it does not enter living cells. The contrast 
agent shortens the relaxation time and thus lower T1 values (23). The inverse of T1 is referred 
to as R1, and the difference in R1 before and after admission of gadolinium contrast is referred 
to as ΔR1. The ratio between myocardial ΔR1 and blood ΔR1 is directly proportional to the 
ratio between myocardial ECV and blood ECV, i.e. the non-hematocrit fraction of whole-blood 
(89). With a known blood and myocardial ΔR1, and a venous hematocrit blood sample, 
myocardial ECV can be calculated (90). Importantly, myocardial ECV by CMR has been 
shown to closely reflect the histologically determined collagen volume fraction, which is the 
histological hallmark of diffuse myocardial fibrosis (30), and associates with worse clinical 
outcomes (31). 
2.4.2 Late gadolinium enhancement 
In myocardial infarction, myocardial cells are damaged due to prolonged ischemia leading to 
rupture of cell walls, cell necrosis, and a loss of cellular function (91). Ischemic 
cardiomyopathy (ICM) is characterized by focal fibrosis following myocardial infarction 
involving the subendocardium, the part of the myocardium most susceptible to ischemia. 
Depending on infarct size, the fibrosis may extend transmurally to the epicardium to a varying 
degree. CMR with late gadolinium enhancement (CMR-LGE) can detect areas of infarction as 
small as one gram of tissue (92). Non-ischemic cardiomyopathy (NICM) is a diverse set of 
pathologies involving the myocardium in the absence of significant coronary artery disease, 
and is characterized by a reduced left ventricular (LV) systolic function (93). NICM is 
associated with non-ischemic focal fibrosis patterns typically engaging the mid-wall, 
epicardium, or the global endocardium. Due to its high resolution and high contrast-to-noise 
ratio, CMR-LGE provides a clear differentiation between myocardial scar patterns in ICM and 
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Figure 2.11. Hyperenhancement patterns in ischemic and nonischemic disease 
 
 
Figure 2.11: Hyperenhancement patterns of ischemic and non-ischemic myocardium in 
cardiovascular magnetic resonance short axis slices. In ischemic disease, the endocardium is 
hyper enhanced, as the subendocardium is the part of the myocardium most susceptible to 
ischemia. In non-ischemic disease, isolated mid-wall, epicardial, or global endocardial, 
hyperenhancement patterns are present. HE indicates hyperenhancement. Figure reproduced 
from Mahrholdt, et al (94), with permission.  
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2.4.3 Volume, mass, and function 
Due to its excellent reproducibility and accuracy, CMR is the gold standard for assessing left 
ventricular volumes, mass, and systolic function (95). CMR uses cine imaging by repeatedly 
imaging the heart, one slice at a time, throughout the cardiac cycle. Below follows a list of 
CMR parameters commonly used in clinical evaluations, as well as within the scoop of this 
thesis. Several sex- and age-specific values of normality for these measures have been 
proposed. The studies in this thesis have used the reference values based on the work by 
Maceira, et al (96), unless otherwise specified.   
• Left ventricular ejection fraction (LVEF) is the fraction, in percent, of blood in the 
left ventricle that is pumped out into the circulation system at every heart beat. Left 
ventricular ejection fraction (LVEF) is a widely-used marker for HF, but has well-
known limitations in diagnosing HF (97). Nevertheless, LVEF is associted with adverse 
prognosis in the setting of HF (97, 98). 
• Global longitudinal strain (GLS) reflects LV myocardial shortening, in percent, in 
the longitudinal direction, and is a measure of LV function. GLS shows prognostic 
value superior to LVEF (99), and new findings suggest GLS to be a better marker for 
impaired LV function than LVEF in patients with preserved LVEF (100). The heart 
also contracts in the circumferential direction, and that shortening in percent is referred 
to as global circumferential strain (GCS), and is also a marker for impaired LV function 
(100). 
• Left ventricular mass (LVM) is the mass, in grams, of the myocardium. An increase 
in LVM is an independent risk factor for cardiovascular events (101). Due to the wide 
distribution on LVM in a normal population, it is often adjusted by indexing to body 
surface area (BSA, LVMI) (102).  
• Left ventricular end diastolic volume (LVEDV) is the volume, in millilitres, of the 
left ventricle at the end of diastole – right before the onset of LV ejection, and thus 
when the LV volume is the largest. In a healthy heart, the volume is normal, but 
increases in certain pathologies, such as eccentric hypertrophy or dilated 
cardiomyopathy. Similar to LVM, EDV is often adjusted to BSA. The relationship 
between LVM and LVEDV can be used to estimate the left ventricle global wall 
thickness (GT), which is useful when characterizing different patterns of LVH (26). 
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Figure 2.12. Different CMR images 
 
Figure 2.12: Different CMR images from the top left: cine image(s), used to quantify left 
ventricular mass and assess left ventricular volumes and function; feature tracking, used to 
quantify global longitudinal strain, which is shortening, in percent, in the longitudinal 
direction; late gadolinium enhanced image, used to quantify myocardial infarction and non-
ischemic scar size, and; extracellular volume fraction maps, which has been shown to correlate 
to diffuse myocardial fibrosis. 
 
2.5 PREDICTION MODELS 
It has been shown that conventional ECG criteria lack sensitivity and specificity in detecting 
cardiac disease. In this thesis, we investigate if any – or if a combination of any – A-ECG 
parameters can improve the ability to diagnose LVH. A-ECG analysis encompasses 
approximately 500 unique ECG parameters. Finding the optimal parameters can be done 
through statistical feature selection methods in which an algorithm is trained to find the 
parameters that best predict a certain binary event, e.g. presence of LVH, or death. The selected 
A-ECG parameters can be expressed as a score, indicating the likelihood of having an event. 
The score can be modeled to range from 0–100%, where a higher score is associated with a 
higher likelihood of event. Importantly, previously created A-ECG scores have been shown to 
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be both more sensitive and more specific at identifying disease compared conventional ECG 
criteria (4). An appropriate feature selection strategy is necessary in order to allow facilitation 
of data understanding and visualization, reduced training and utilization times, reduced storage 
management, and avoiding overly complex and overfitted prediction models (103).  
Figure 2.13. Fitting of binary classification  
 
Figure 2.13: Concept of model regularization to fit a binary classification, here to separate 
the blue dots from the red dots. Depending on the degree of the polynomial function, the fitting 
can be; plausibly fitted, underfitted, or overfitted, respectively. In mathematics, and statistics, 
model regularization is used to add information to a model, such as a penalty, to obtain a 
plausibly fitted classification while preventing overfitting. Reproduced from Galbusera, et al 
(104), with permission. 
Feature selection can be performed forwards or backwards. Forward selection is a technique 
whereby one starts with an empty model, i.e. no parameters, and lets the model try parameters, 
one at a time, that correlate best with the event. Subsequently, the remaining candidate 
parameters are tried to see which one adds the most predictive performance. This continues 
until a specified number of parameters are added to the model, or when no parameter adds 
further predictive capacity. Conversely, a backward elimination selection starts with a model 
with all parameters, and eliminates parameters that contribute the least toward predictive 
performance, one at a time. It has been argued that the forwards selection method outperforms 
the backwards selection method (105), and forwards selection was used within the scope of 
this thesis. However, backwards elimination suffers less from feature interaction since it starts 
with the full model and eliminates parameters that interact with the parameters that perform the 
best (105). The parameters are typically selected based on a variable ranking mechanism. 
However, a parameter that is useless by itself, can become powerfully predictive together with 
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another parameter, and parameters that correlate highly will be redundant for the model because 
no additional information is gained by adding them (103).  
It is generally accepted that the number of parameters used to predict an outcome should be 
restrained to a maximum of one parameter per ten events (106). This approach is used to reduce 
the risk of an over-fitted model, as the requirement of events grows exponentially, referred to 
as “the curse of dimensionality” (107). When the optimal set of parameters for predicting an 
outcome have been selected, the accuracy and model performance is tested and evaluated.  
The performance of a model is best evaluated by applying it to an independent cohort compared 
to those used to develop the model. As that require a lot of data, there are strategies to derive 
new groups of patients for the evaluation, such as k-fold cross-validation and bootstrapping, 
respectively. Bootstrapping, used in the studies in this thesis, is a resampling method in which 
the whole cohort is randomly sampled a set amount of times, resulting in different “new” 
groups.  
2.5.1 Feature selection methods 
Feature selection may be adopted when there is a limited knowledge about the significance of 
the parameters for a certain outcome or purpose, and stepwise regression may be used to 
identify the significant parameters (108). Within the scoop of this thesis, the feature selection 
method we adopted was stepwise forward logistic regression. In comparison to linear 
regression that assesses the relationship between a dependent variable and an explanatory 
variable (or independent variable), logistic regression compares the relationship between a 
binary dependent variable and an explanatory variable. A binary variable has two possible 
mathematical values, e.g. “0” and “1”. This can translate to e.g. yes and no, or survived and 
died, and is thus suitable for outcomes analyses.  
Besides logistic regression, several other feature selection methods are used in statistical 
modeling. Therefore, we also investigated Lasso, Ridge and Elastic net regression techniques 
when designing Study IV. Briefly, what these regression techniques have in common is that 
they introduce a bias in the regression in order to prevent overfitting in particular highly linearly 
related measures, so called multicollinearity. 
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2.5.2 Statistical diagnostic tests 
Two major elements associated with clinical diagnostic tests are the sensitivity and specificity. 
Sensitivity is the proportion of sick individuals that are correctly diagnosed as sick by a test 
(true positives), and specificity is the proportion of healthy individuals that are correctly 
diagnosed as healthy by a test (true negatives). As sensitivity and specificity are proportions, 
confidence intervals (for proportions) can be calculated (109). Sensitivity and specificity can 
only be determined if the true diagnosis is known (110). Receiver operating characteristic 
(ROC) curves can be used to find the optimal cutoff by plotting all possible cutoffs resulting in 
a visual representation of the sensitivity and specificity at different cutoff. Depending on what 
is clinically desired with regards to the trade-off between a high sensitivity or specificity, the 
criteria or cutoff for a diagnostic test can be set accordingly. In a clinical setting it is common 
to optimize the sensitivity at the expense of a lowered specificity (111). 
Table 2.1. Sensitivity and specificity 
 Disease present Disease absent 
Positive test True positive (TP) False positive (FP) 
Negative test False negative (FN) True negative (TN) 
Table 2.1: Sensitivity is calculated as TP / (TP + FN), and shows the fraction of patients with 
disease that are correctly diagnosed by a test. Specificity is calculated as TN / (TN + FP), and 
shows the fraction of patients with no disease (healthy) that are correctly diagnosed by a test. 
Bayes’ theorem involves an a priori analysis used to decide the probability of an event. A 
patient may present with a history and clinical findings suggesting a high risk of having an 
event, e.g. LVH. Even though a certain diagnostic test may suggest that no disease is present 
in the patient, the result should be interpreted with caution based on clinical status, or vice 
versa. In addition to sensitivity and specificity, predictive values are used to evaluate the 
accuracy of the diagnostic test. The positive predicate value (PPV) is the proportion of positive 
test results that are truly positive, and the negative predictive value (NPV) is the proportion of 
negative test results that are truly negative.  
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3 AIMS 
The overall aims of this thesis were to investigate the diagnostic and prognostic ability of A-
ECG measures in heart disease, using CMR as the gold standard for disease. 
The specific aims for each study were: 
I. To investigate how LVMI and diffuse myocardial fibrosis, measured as ECV, influence 
the ECG patterns commonly interpreted as LVH. 
 
II. To investigate electrocardiographical differences in LVMI and GTI by creating A- 
ECG scores for increased LVMI and GTI, respectively, and compare to conventional 
ECG criteria for LVH. 
 
III. To define LVER based on the deviation from normal angles in the VCG, and compare 
the diagnostic and prognostic value of LVER to conventional ECG LVH criteria. 
 
IV. To create ECG and CMR prognosis scores, respectively, to compare the prognostic 
value of the scores, and to investigate to what extent the ECG score can be explained 
by CMR measures. 
  
 











“Biomedical statistics is the poetry of biomedical science” 
– Erik B. Schelbert 
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4 MATERIALS AND METHODS 
4.1 STUDY POPULATIONS 
In all four studies, the study population consisted of retrospectively identified patients referred 
for a clinical CMR imaging scan at the University of Pittsburgh Medical Center (UPMC), PA, 
USA. In addition, Study III included patients who had undergone cardiac imaging at one of the 
seven following sites: Lund University Hospital, Lund, Sweden; Brooke Army Medical Center, 
San Antonio, TX, USA; Texas Heart Institute, TX, USA; the University of Texas Health 
Sciences Center, San Antonio, TX, USA; the University of Texas Medical Branch, Galveston, 
TX, USA; St. Francis Hospital, Charleston, WV, USA; and the Universidad de los Andes, 
Mérida, Venezuela (4). Study III also included healthy volunteers from NASA’s Human Test 
Subject Facility, Houston, TX, USA; the Universidad de los Andes, and Lund University 
Hospital (4). 
The study patients from UPMC partially overlapped among the studies, but the patients in Study 
II were included according to more strict criteria than those in Study III and IV, and the patients 
in study I were more strictly identified than those in Study II. All study participants provided 
informed consent, and all studies were approved by the local institutional review boards. 
4.1.1 Study I 
To avoid ECG confounders beside LVMI and ECV, the study population in Study I consisted 
of carefully selected patients from a database of patients referred for a CMR scan at UPMC 
between year 2010 and 2014. Inclusion criteria were an ECG with sinus rhythm with a heart 
rate <100 beats/min acquired within 30 days of CMR. Exclusion criteria included atrial 
fibrillation or flutter, bundle branch- or fascicular block, abundant premature atrial 
contractions, abundant premature ventricular contractions (bigeminy or trigeminy), paced 
rhythm, treatment with digitalis, previous MI or non-ischemic cardiomyopathy by LGE-CMR, 
previous cardiac surgery, pathologic stress perfusion CMR, cardiac amyloidosis, severe 
valvular disease by CMR, significant coronary artery stenosis by invasive angiography, EDVI 
>120 g/m2, and BMI <18 or >30 kg/m2. Because the aim of the study was to investigate how 
LVH-associated ECG parameters were affected by ECV and LVMI respectively, we aimed to 
include subgroups of equal size with all combinations of normal or increased ECV and LVMI, 
respectively. In a database of 1707 patients, we first applied inclusion and exclusion criteria 
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which yielded a cohort of 537 eligible patients. Next, we aimed to select n=20 patients with 
each combination of normal or increased ECG and LVMI, respectively. However, due to a 
shortage of patients eligible for the fourth subgroup, only 17 were available. Thus, a total of 77 
patients were ultimately included in Study I, as shown in Figure 4.1. 
Figure 4.1. Flowchart of patient selection in Study I 
 
Figure 4.1: The flow chart shows the patient selection algorithm in Study I. In a database of 
1707 patients, 573 patients were eligible for the study. To investigate the study hypothesis, a 
total of 77 patients were ultimately included in the study. The cut-off separating normal from 
increased myocardial extracellular volume fraction (ECV) was 28.5%, and the cutoff 
separating low from high left ventricular mass index (LVMI) was 55 g/m2. Figure reproduced 
from Study I with permission.  
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4.1.2 Study II 
The patients in Study II were identified retrospectively from the UPMC database. Inclusion 
criteria were an ECG with sinus rhythm acquired within 30 days of a contrast-enhanced CMR 
including measures of LVEDV and LVM. The following potential ECG confounders were 
excluded: heart rate ≥100 beats/min, QRS duration ≥120 ms, atrial fibrillation or flutter, 
abundant premature atrial or ventricular beats (bigeminy or trigeminy), bundle branch blocks, 
treatment with digitalis, and inadequate ECG records. The following CMR confounders were 
excluded: previous MI or non-ischemic myocardial scar by LGE-CMR, dilated or hypertrophic 
cardiomyopathy, severe valvular disease, amyloidosis, and significant coronary artery stenosis 
by stress perfusion CMR. Lastly, the following clinical parameters were excluded: previous 
revascularization, and any prior cardiac surgery. From a database of 1828 patients, 485 patients 
were eligible for the study. 
4.1.3 Study III 
Study III consisted of four sub-cohorts: 1) healthy volunteers to define sex-specific normal 
values for LVER (Healthy-Derivation cohort, n=921); 2) a separate set of healthy volunteers 
used to evaluate the study measures (Healthy-Validation cohort, n=461); 3) clinical patients 
with at least moderate LVH by cardiac imaging to evaluate the study measures (Imaging-LVH 
cohort, n=225); and 4) clinical patients referred for CMR imaging who also had follow-up data 
on all-cause death or hospitalization for heart failure, to evaluate the diagnostic and prognostic 
value of the study measures (Clinical-Consecutive cohort, n=783). 
The three sites from where the healthy volunteers were identified have been described 
previously. In summary, all healthy volunteers had no evidence of cardiovascular or other 
systemic disease based on a negative history and a physical examination. Furthermore, they 
were asymptomatic, and had a clinically normal conventional ECG. Asymptomatic volunteers 
who were active smokers, or received treatment for hypertension or diabetes were excluded. 
The Imaging-LVH cohort was included from seven different sites, as described previously. In 
brief, inclusion criteria included an ECG with a QRS duration <120 ms acquired within 30 days 
of the cardiac imaging examination, and at least moderate LVH according to the clinical 
assessment of the reporting imaging physician or the guidelines of the American Society of 
Echocardiography (112). Exclusion criteria were non-sinus or paced rhythm, right or left 
bundle branch block, pre-excitation, incomplete ECG records, and imaging findings of a 
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predominant cardiac pathology other than LVH, such as MI or non-ischemic cardiomyopathy, 
and moderate or greater valvular disease by echocardiography. 
The Clinical-Consecutive cohort was identified from the UPMC database of 1828 consecutive 
clinical patients who underwent a CMR at UPMC between 2008 and 2017, and had a follow-
up time until April 2018. A total of 783 patients met all inclusion but no exclusion criteria. 
Exclusion criteria were atrial fibrillation or flutter, paced rhythm, abundant premature 
ventricular contractions (bigeminy/trigeminy), hypertrophic cardiomyopathy, congenital heart 
disease, Takotsubo cardiomyopathy, siderosis, amyloidosis, Fabry’s disease, and poor CMR 
image quality.  
4.1.4 Study IV 
The fourth study consisted of the same patients (n=783), and with the same inclusion and 
exclusion criteria, as the Clinical-Consecutive cohort in Study III. 
 
4.2 ECG ACQUISITION AND ANALYSIS 
Standard 12-lead ECGs were recorded under clinical conditions using the local ECG machines. 
ECGs were typically recorded on a GE ECG machine and stored into the digital database 
(MUSE® Cardiology Information System, Version 8.0 SP2, GE Healthcare, Chicago, IL, 
USA). Clinical ECGs were recorded for a duration of 10 seconds, and at a sample rate of 250 
Hz or 500 Hz. In Study III, the healthy volunteers and patients in the Imaging-LVH cohort had 
5-minutes ECG recordings sampled at 1000 Hz. All ECGs were exported from the respective 
databases into anonymized .xml files with coded subject identification. The digital semi-
automatic A-ECG software CardioSoft® (NASA, Johnson Space Center, Houston, TX, USA) 
was used to analyze all ECG files. 
4.2.1 Conventional ECG LVH measures 
A-ECG analysis includes measures of conventional P-, QRS- and T-wave amplitudes, 
durations, and axes. Conventional ECG criteria for LVH are based on increased QRS 
amplitudes and durations. In Study I-III we investigated the following established criteria, and 
all measures were performed and calculated digitally: 
 
  43 
1. Sokoloy-Lyon index, defined as the sum of the the larger R wave in lead V5 (RV5) or 
RV6 and Sv1 voltage, where LVH is defined as a sum >3.5 mV (113). 
2. Cornell voltage, defined as the sum of RaVL and SV3 voltage, where LVH is defined as 
sum >2.0 mV for women and >2.8 mV for men (70). 
3. Cornell voltage product, defined as the product of the Cornell voltage and the QRS 
duration, where LVH is defined as ≥244mV•ms (114). 
4. The longest QRS duration in any lead, defined as the beginning of the Q-wave to the 
end of the S-wave, where LVH was defined as a QRS duration ≥100 ms (115). 
4.2.2 Vectorcardiographic measures 
All VCGs were derived from the 12-lead ECG using Kors’ transform (3, 54). The VCG shows 
the spatial direction and magnitude of the electrical vector in the three-dimensional space, for 
each of the three perpendicular two-dimensional planes, namely the frontal, horizontal, and 
(left) sagittal plane. From this three-dimensional space, several different VCG measures were 
obtained, including: 
• The direction and magnitude of the QRS loop and T loop vector in space, expressed as 
elevation or azimuth angles from a predefined plane. 
• The morphologic configuration of the QRS loop and T loop, such as Tavplan (116, 
117).  
• The direction and duration of vectors and whole vector loops. 
• The QRS-T angle, defined as the difference between the mean or peak angles of the 
QRS and T loop. 
The elevation angle is the angle between the vector and the respective plane. Forward directions 
are defined as 0–180°, and backward directions are defined as 0– -180°. When observing a 
torso in the upright position from the front, 0° is defined as a vector pointing to the left in the 
frontal plane, and as a vector pointing to the back in the horizontal and left sagittal plane. P 
loop measures were not used within the scoop of this thesis since 10-second ECG recordings 
are not long enough to achieve an adequate signal-to-noise ratio for deriving P loops. 
4.2.3 QRS wave and T wave complexity measures.  
Mathematical SVD was used for detailed studies of QRS and T wave complexity. This 
rendered eigenvectors 1 through 8 for the respective waves.  
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4.3 CMR ACQUISITION AND ANALYSIS 
All CMR acquisition was performed at UPMC CMR Center, PA, USA, and images were 
analyzed using the local Leonardo work station (Siemens Healthcare, Erlangen, Germany). 
CMR images were acquired using a scanner with a field strength of 1.5 T (Magnetom Espree, 
Siemens Healthcare, Erlangen, Germany) and a 32-channel phased array surface coil.  
4.3.1 Dimensions, volumes, and late gadolinium enhancement  
The CMR exams included standard breath-held segmented cine imaging with a steady-state 
free precession (SSFP) sequence. Short-axis stacks were acquired and used to measure LV 
mass, volumes, and ejection fraction in end-systole and end-diastole. Typical acquisition 
parameters were field of view 360x270 mm2, matrix size 256x128 pixels, and slice thickness 
6 mm. Ten minutes after a 0.2 mmol/kg intravenous bolus injection of gadoteridol (Prohance, 
Bracco Diagnostics, Princeton, NJ, USA), LGE imaging was performed using a phase-sensitive 
inversion recovery (PSIR) pulse sequence. If a patient could not breath-hold properly, a single-
shot motion corrected PSIR sequence was used (118, 119). Global wall thickness, defined as 
the mean wall thickness of the whole left ventricle in end-diastole, measured in millimeters, 
was calculated according to previously validated methods (27) as:	
𝐺𝑇 = 0.05 + 1.60 ∙ 𝐿𝑉𝑀/.01 ∙ 𝐿𝑉𝐸𝐷𝑉4/.56 
4.3.2 Quantification of extracellular volume fraction 
Quantitative T1 maps were acquired using an ECG-gated single-shot-modified Look Locker 
inversion recovery sequence (MOLLI), and the maps were used to calculate ECV. Native T1 
maps were acquired followed by a bolus injection of a gadolinium-based contrast agent, and 
acquisition of post-contrast T1 maps. T1 was measured in areas without LGE, and in the middle 
third of the myocardium to avoid partial volume effects. ECV was calculated as: 
ECV	 = 	λ ∙ (1 − hematocrit) 
where λ =ΔR1myocardium/ΔR1bloodpool and ΔR1=1/T1postcontrast - 1/T1precontrast (90). ECV in the 
blood was calculated from a circular region traced in the middle of the blood pool to avoid 
partial volume effects from papillary muscles. The final myocardial ECV values were averaged 
from basal and mid-ventricular short axis slices. Apical slices were not used to calculated ECV 
due to obliquity between the image plane and myocardium, which could introduce partial 
 
  45 
volume effects (18). Hematocrit measures were acquired on the day of CMR and analyzed in 
the clinical laboratory.  
Figure 4.2. Distribution of Gd contrast and calculation of ECV 
 
 
Figure 4.2:  Gadolinium-based contrast agents (Gd) distribute freely in the extracellular space 
and do not enter living cells. Myocytes, myocardial capillaries, extracellular matrix with 
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collagen, plasma, erythrocytes, and Gd molecules are illustrated in the figure. The upper panel 
shows normal myocardium before and after contrast, and with a normal distribution of Gd in 
the myocardial interstitium after administration. The lower panel shows fibrotic myocardium 
before and after contrast, and with an increased distribution of Gd in the myocardial 
interstitium after administration. The middle panel shows the computational steps for 
extracellular volume fraction measurement from T1 images. Figure reproduced from Wong, et 
al (120), with permission.  
4.3.3 Quantification of global longitudinal strain 
GLS was analyzed using a semi-automated tissue feature tracking software (CVi42, Circle 
Cardiovascular Imaging Inc., Calgary, Canada). Epicardial and endocardial borders were 
traced manually in 2-, 3-, and 4 chamber end-diastolic images. Strain analysis tracings were 
inspected visually throughout the cardiac cycle, and if tracings deviated from myocardial 
movement, manual adjustments were made. 
 
4.4 ECHOCARDIOGRAPHIC ANALYSIS 
In Study III, echocardiography was used to diagnose LVH besides CMR. By echocardiography, 
LVH was defined as moderate or greater as reflected in the clinical report, according to the 
guidelines of the American Society of Echocardiography (112). 
 
4.5 STATISTICAL ANALYSIS 
In Study I, statistical analyses were performed using SPSS version 23 (IBM Corp, Armonk, 
NY, USA). In Study II-IV, statistical analyses were performed using R version 3.4.3 (R 
Foundation for Statistical Computing, Vienna, Austria) with, among others, packages dplyr 
(121) for data transformation, and ggplot2 (122) for data visualization. A p-value <0.05 was 
considered statistically significant. 
The Kolmogorov-Smirnov test was used to test whether variable distribution deviated from 
normal distribution. Differences in normally distributed data were compared with the unpaired 
Student’s t test, or analysis of variance (ANOVA), as appropriate, and described using mean 
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and standard deviation (SD). Differences in non-normally distributed data were compared 
using Mann-Whitney U test, or Kruskal-Wallis test, as appropriate, and described using median 
and interquartile range (IQR). Differences in proportional data were compared using Chi-
squared test, and described as the quantity and as a percentage. Linear correlations were 
evaluated using Pearson’s correlation coefficient (r), and expressed as its square (R2). 
Univariable and multivariable Cox regression (proportional hazards regression) analyses were 
used to calculate hazard ratios (HR) for outcome and survival analyses, and Kaplan-Meir plots 
were created for endpoint visualizations. 
The diagnostic and prognostic scores for a binary outcome used in Study II and IV were derived 
using continuous A-ECG measures and stepwise forward logistic regression. A maximum of 
one parameter per ten events was accepted for the scores (106). To determine the diagnostic 
accuracy of the derived scores, the area under the ROC curve (AUC) was calculated and 
bootstrapped 2000 times to obtain ninety-five percent confidence intervals (95% CI). When 
more than one score was derived, the score with the highest AUC was chosen. The Youden 
index (123) was used to identify the cut-off for the scores that optimized sensitivity and 
specificity. The logistic scores were constructed to show a likelihood of event, ranging from 
0–100%, and calculated from the logistic regression as: 
𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑	𝑜𝑓	𝑒𝑣𝑒𝑛𝑡 =
1
1 + 𝑒RSTUVWXYZ	[X\VU	VU[SZ] ∙ 100	 
where the numerical score result is the calculated value for each study patient based on their 
A-ECG measures. In Study II, DeLong’s test (124) was used to compare the AUC between 
different scores and measures. In Study IV, besides sensitivity and specificity, the positive 
predictive value (PPV) and negative predictive value (NPV) were calculated to evaluate the 
performance of the score. Lastly, a recently published prognostic ECG score by Aro, et al 
(125), (Aro ECG risk score) was also investigated which was defined as the fulfillment of four 
or more of the following criteria: QRS duration >110 ms, QTc time > 450 ms in men and > 
460 ms in women, heart rate >75 bpm, frontal plane QRS-T angle >90°, Tpeak–Tend duration 
>89 ms, electrocardiographic LVH, delayed QRS transition zone, or a delayed intrinsicoid 
deflection, assessed from the 12-lead ECG. 
  
 




















 “Expect nothing and appreciate everything” 
– Unknown  
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5 RESULTS AND DISCUSSION 
We investigated if we could find an explanation regarding why the ECG criteria for LVH are 
poor, and if ECG diagnosis of LVH could be improved. In Study I we found that diffuse 
myocardial fibrosis is associated with reduced ECG voltage amplitudes, which are typically 
used to diagnose LVH. This provided mechanistic insight which can, in part, explain the limited 
sensitivity of the ECG for detecting increased LV mass. Based on these results, we sought to 
investigate whether A-ECG parameters could be used to improve the ECG-based diagnosis of 
LVH. In Study II we found that A-ECG parameters could better detect LVH than conventional 
ECG LVH criteria. We further found electrocardiographic differences between hypertrophy 
with either increased LVMI or GTI, or a combination of both. In Study III we chose to use the 
term LVER in order to emphasize our focus on electrical changes considered associated with 
LVH, but which can occur independently of anatomical LVH. We found that LVER, defined 
as a spatial peaks QRS-T angle greater than its normal distribution in a healthy population, 
improved the diagnosis of LVH compared to conventional ECG LVH criteria. Furthermore, 
LVER also provided prognostic information. With those results, we sought out to optimize an 
ECG-score for survival. In Study IV we found that a new simple ECG score predicted 
outcomes beyond known powerful prognostic CMR measures. 
5.1 THE IMPACT OF DIFFUSE MYOCARDIAL FIBROSIS UPON ECG 
MEASURES OF LEFT VENTRICULAR HYPERTROPHY 
Study I was a mechanistic study designed to investigate how diffuse myocardial fibrosis, 
measured as ECV, affects voltage measures and QRS duration, on the conventional ECG 
interpreted as LVH. Diffuse myocardial fibrosis was previously only diagnosed through 
invasive biopsy, but has been histologically validated to be strongly correlated to T1 
measurements by CMR (30, 34, 126-129). Despite the central diagnostic role of the ECG in 
cardiology, no data existed on the contributions of diffuse myocardial fibrosis to the ECG 
changes in LVH. The diagnostic performance of conventional ECG LVH criteria vary greatly 
(68), and it may be due to confounding factors such as diffuse myocardial fibrosis.  
To investigate the effects of diffuse myocardial fibrosus upon ECG measures of LVH, we 
studied a carefully selected group of patients without any other apparent clinical, CMR, or ECG 
co-morbidities that could potentially influence the ECG besides diffuse myocardial fibrosis and 
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increased LV mass. See Figure 4.1 for a detailed list of exclusion criteria. The results showed 
a positive relationship between LVMI and the investigated ECG measures, and an inverse 
relationship between ECV and the investigated ECG measures. 
Figure 5.1. Linear correlations between LVMI, ECV and ECG LVH measures  
 
 
  51 
Figure 5.1: Linear correlations between ECG measures Sokolow-Lyon index, Cornell voltage, 
12-lead voltage sum and QRS maximum spatial magnitude, and LVMI and ECV, respectively. 
Note that LVMI is positively correlated with all voltage measures (subfigures A, C, E, G), 
whereas ECV is inversely correlated with all voltage measures (subfigures B, D, F, H). The 
QRS duration was neither correlated to LVMI nor ECV. Figure reproduced from Study I, with 
permission. 
A plausible physiological explanation for the results may be that increased LVMI gives rise to 
longer and larger living electrical activation patterns with increased QRS amplitudes (78). 
However, in LVH there is a process beyond the increase of mass, including myocyte apoptosis, 
changes in electrical phenotype, and alterations in the composition and quantity of the 
extracellular matrix that may interfere with QRS voltage (78). Furthermore, an increase in 
ECV, consisting mostly of collagen, may serve as an electric insulator and decrease the voltage 
recorded by ECG. This phenomenon has been observed in other cardiac conditions such as 
infiltrative cardiomyopathies, and after myocardial infarction (130, 131). However, patients 
with such diagnoses were excluded from the study. We did not find any correlation between 
QRS duration and increased LVMI, as have been reported in previous studies (132-135). 
 
5.2 ADVANCED VS CONVENTIONAL ECG IN LVH DIAGNOSIS 
To our knowledge, previous ECG LVH studies have not investigated whether different LVH 
sub-patterns have different electrocardiographic characteristics. An established classification 
of LVH commonly used in imaging studies divides LVH into the three patterns: concentric 
remodeling, eccentric hypertrophy and concentric hypertrophy, respectively, based on LVMI 
and some measure of relative wall thickness, e.g. GTI (26). Therefore, the electrocardiographic 
differences in increased LVMI and GTI, respectively, were investigated. Similar to Study I, we 
excluded patients with potential CMR, ECG, or clinical confounders that could possibly affect 
the ECG. Even though ECV affects the ECG, as was found in Study I (75), patient with 
increased ECV were not excluded. The feature selection method stepwise forward logistic 
regression was employed to identify A-ECG parameters that would comprise a diagnostic score 
that could best identify increased LVMI, and GTI, respectively. We found that different 
patterns of LVH indeed differed in their electrocardiographic manifestation by A-ECG.  
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The increased LVMI A-ECG score, and increased GTI A-ECG score had a higher AUC than 
all conventional ECG LVH parameters in diagnosing increased LVMI, and GTI, respectively.  
Figure 5.2. AUC for scores for increased LVMI and GTI 
 
Figure 5.2: The area under the curve (AUC) for the increased LVMI A-ECG score and GTI A-
ECG score, respectively, in detecting increased LVMI and GTI, respectively. The A-ECG 
scores had a higher AUC than Cornell voltage, Cornell product and Sokolow-Lyon index for 
detecting increased LVMI and GTI, respectively. Interestingly, the GTI A-ECG score could 
detect increased LVMI on par with the dedicated LVMI A-ECG score. Figure reproduced from 
Study II with permission. 
Compared to conventional ECG LVH criteria (Sokolow-Lyon index, Cornell voltage, and 
Cornell voltage product) which are based on increased voltage amplitudes and prolonged QRS 
durations, the diagnostic A-ECG parameters for detecting increased LVMI, and GTI also 
included VCG parameters and measures of QRS wave complexity. It may be that these 
measures have a more global and varied diagnostic performance than solely increased voltages. 
Essentially all measures that were incorporated into the diagnostic scores, as presented in Table 
5.1, have previously been studied in ventricular hypertrophy (64, 136-142). If patients with 
increased ECV had been excluded, additional, or different, voltage measures may have been 
significant for the diagnosis. However, as the study population was selected from patients 
undergoing a clinically indicated CMR scan, the results reflect a general group of patients with 
LVH, which was the investigated group of interest. The results give further insight into the 
limited sensitivity of the conventional ECG based on the different electrical properties captured 
by A-ECG. The results also highlight diagnostic information present in the ECG that can 
improve clinical LVH diagnosis. 
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Table 5.1. A-ECG parameters in the increased LVMI and GTI scores 
 
ECG parameter Z-value p value AUC (95% CI) 
Increased LVMI score 
1) The area of the QRS vector 
magnitude (mV•s) 




2) The QRS loop area outside 
the left lower quadrant in 
the left sagittal plane (%) 
-3.3 <0.001 
3) T wave amplitude in lead 
aVR (µV) 
-3.2 0.001 
4) QTc (ms) 2.7 0.007 
Increased GTI score 
1) 6th Eigenvalue (singular 
value) of the QRS 









The azimuth of the 
maximum QRS magnitude 
in the left sagittal plane 
(radians) 
3.5 <0.001 
4) T wave amplitude lead I 
(µV) 
-3.5 0.002 




5.3 LEFT VENTRICULAR ELECTRICAL REMODELING – DIAGNOSIS AND 
PROGNOSIS BEYOND ECG LVH 
Electrical and anatomical properties of the heart are fundamentally different. Importantly, both 
properties are important as they predict prognosis independently of each other (24). Although 
A-ECG measures have a higher diagnostic performance compared to conventional ECG for 
diagnosing LVH as determined by imaging (143), there are still several important and related 
issues. First, the limited diagnostic performance of ECG criteria for detecting anatomical 
changes present in LVH may likely be related to the inherent differences between 
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electrophysiology and anatomy. Second, the term LVER has been suggested to be more 
appropriate when referring to the electrical changes present in LVH (144, 145). We therefore 
considered it a reasonable approach to define LVER in terms of electrical changes in the 
myocardium based on deviation from normality observed in healthy individuals, rather than 
based on a non-electrical anatomical marker such as LVH. Study III examined the spatial peaks 
QRS-T angle in healthy individuals, patients with LVH, and clinical consecutive patients. The 
QRS-T angle can be derived from a digital 12-lead ECG, but it can also be manually estimated 
from a paper-based 12-lead ECG (146). 
In Study IV, LVER was defined as greater than the sex-specific 97.5th percentile of normal for 
the VCG spatial peaks QRS-T angle based on healthy volunteers (Healthy-Derivation cohort, 
n=921), resulting in an angle ≥40° in females and ≥55° in males. LVER was absent in nearly 
everyone in a separate cohort of healthy volunteers (Healthy-Validation cohort, n=461). 
Furthermore, LVER was present in nearly all subjects with an isolated LVH (Imaging-LVH 
cohort, n=225). See Figure 5.3 for the sensitivity and specificity for the LVER criterion and 
conventional ECG criteria in the respective cohorts. In the Clinical-Consecutive cohort, 
however, the sensitivity and specificity of the LVER criterion to diagnose LVH was not as 
excellent as in the prior cohorts. This may be due to confounding co-morbidities in the clinical 
cohort, such as non-ischemic or ischemic myocardial scar, or other co-morbidities since they 
were referred for a clinical CMR scan. Interestingly, LVER was also present in patients in the 
Clinical-Consecutive cohort that did not have LVH. This illustrates that LVER identifies an 
electrical remodeling process beyond LVH, and may thus be missed by anatomical imaging. 
We found that the QRS-T angle improved the diagnosis of LVH beyond conventional ECG 
criteria, in accordance with previously publishes results (147). 
Patients with LVER had a worse prognosis with regards to the combined end-point survival 
free from hospitalization for heart failure and death compared to those without. The same was 
found in all investigated conventional ECG LVH criteria except the Sokolow-Lyon index. This 
study showed an improved diagnostic performance, and a prognostic performance beyond that 
of conventional ECG LVH criteria. Furthermore, it highlighted the importance of separating 
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Figure 5.3. LVER and conventional ECG criteria in LVH 
 
Figure 5.3: The sex-specific sensitivity and specificity of the conventional ECG measures 
Sokolow-Lyon index, Cornell voltage, Cornell voltage product, and QRS duration, 
respectively, and of the LVER criterion for detecting imaging-verified LVH. LVER was defined 
as spatial QRS-T angle ≥40° for females and ≥55° for males, and had a higher sensitivity for 
LVH in both the Imaging-LVH and Clinical-Consecutive cohort compared to the other ECG 
measures (p<0.05 for all). Among females in the Healthy-Validation cohort, the LVER 
criterion had a higher specificity than the QRS duration (p<0.001), did not differ from that of 
Cornell voltage or Sokolow-Lyon index (p>0.05 for both), and had a lower specificity than 
Cornell product (p<0.05) in detecting LVH. Among males the Healthy-Validation cohort, the 
LVER criterion had a higher specificity than the QRS duration (p<0.001), did not differ from 
Sokolow-Lyon index (p>0.05), and was lower than Cornell voltage and Cornell voltage 
product (p<0.05 for both). In the Clinical-Consecutive cohort, all conventional ECG measures 
had a higher specificity than the LVER criterion (p<0.05 for all) despite its excellent specificity 
in the Healthy-Validation cohort. This suggests possible electrical identification of disease by 
LVER in patients who do not fulfill imaging criteria for LVH. 
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5.4 ADVANCED ECG AND PROGNOSIS 
The VCG spatial peaks QRS-T angle derived from the VCG was found to predict prognosis. 
Therefore, we set out to investigate if other A-ECG parameters have prognostic power, and if 
we could create an ECG prognosis score for the combined endpoint of hospitalization for heart 
failure and death. In Study IV, we adopted the same statistical methods as in Study II, i.e. 
stepwise forward logistic regression to identify ECG parameters for the score. Event after one 
year of CMR was chosen for investigation as it is at a time point when both a clinically and 
statistically meaningful number of events would be observed. A CMR prognosis score for 1-
year event was also derived, and compared to the ECG prognosis score. Besides stepwise 
forward logistic regression, logistic models with a Ridge, Lasso, or Elastic Net penalty, 
respectively, were also evaluated for ECG feature selection. Furthermore, an A-ECG score 
based on Cox regression for continuous was also created to include the information in the 
events that occur continuously.  
The final A-ECG prognosis score for 1-year event included two parameters: 1) the frontal QRS-
T angle (degrees), and 2) the QTc (Bazett (148)) duration (ms). The frontal QRS-T angle and 
QTc where poorly correlated (R2=0.06, p<0.001). The A-ECG score based on Cox regression 
included a combination of 19 parameters (13 A-ECG parameters, and 6 conventional ECG 
parameters). The simpler logistic ECG score had a similar AUC (95% CI) of 0.78 (0.71–0.84) 
compared to the more complex A-ECG score based on Cox regression with an AUC (95% CI) 
of 0.77 (0.69–0.84) at one year of follow-up. Both ECG parameters included in the logistic 
ECG score have previously been shown to predict prognosis. The frontal QRS-T angle is the 
angle between the QRS and T axis in the frontal plane (resembling the three-dimensional spatial 
QRS-T angle). A wide QRS-T angle reflects a dispersion between the depolarization and 
repolarization (57), and is known to be increased as a result of myocardial disease (58). 
Prolonged QTc durations are associated with an increased risk of sudden death and ventricular 
fibrillation (149). 
The prognostic models using logistic regression with a Ridge, Lasso, or Elastic Net penalty, 
respectively, were more complex than the two-parameter ECG score based on stepwise logistic 
regression, and either did not outperform it, or did not provide any meaningful magnitude of 
improved diagnostic performance (results not shown). 
 
  57 
The final CMR prognosis score for 1-year event included two parameters: 1) GLS (%), and 2) 
ECV (%), and had an AUC (95% CI) of 0.77 (0.69–0.84). GLS and ECV were poorly 
correlated (R2=0.05, p<0.001). Both CMR measures are known powerful predictors of adverse 
prognosis. An increase in extracellular volume fraction leads to diastolic and systolic 
dysfunction, as well as an increased risk of arrhythmia and mortality (17). GLS had a superior 
significance for prognosis compared to LVEF, in accordance with previous findings (150). 
Other CMR measures have previously been shown to associate with outcomes, such as LVM 
(101), but were not significantly associated with 1-year event in the current study. The 
difference may be a longer follow-up times than what we investigated (101). 
Figure 5.4. Survival for ECG and CMR prognosis scores 
 
Figure 5.4: Kaplan Meir curves showing survival free from hospitalization for heart failure or 
death for: A. patients with a normal (<50%) or increased (≥50%) ECG prognosis score, B. 
patients with a normal or increased CMR prognosis score, and C. patients with a normal ECG 
and CMR score, patients with a normal ECG score and increased CMR score, and vice versa, 
and patients with both an increased ECG and CMR score. Figure adapted from Study IV. 
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Univariable Cox analysis showed that the CMR prognosis score had a higher univariable 
association with outcomes compared to the ECG prognosis score (χ2 93, HR 2.17 [1.85–2.54], 
and χ2 58, HR 1.79 [1.54–2.08], respectively, p<0.001 for both). Patients who had both a 
positive ECG prognosis score, and a positive CMR prognosis score, i.e. a score/probability 
greater than 50%, had the worst prognosis, see Figure 5.4. 
The Aro ECG risk score (125) was constructed to predict sudden cardiac death and studied to 
specifically compare a logistic prognostic score to a point-based prognostic score. In our 
cohort, the Aro ECG risk score had a limited power of predicting outcomes, with an AUC of 
0.65 (0.57–0.72). Discrepancies in the final end-point, and patient selection in the current and 
original cohort may be the reason to the lower performance of the Aro ECG risk score in our 
cohort. Besides the current study, the ECG has previously been compared to cardiac imaging 
modalities with regards to prognosis, and found to have an independent or incremental 
prognostic power. For instance, it has been evaluated in patients with myocardial infarction 
with non-obstructed coronary arteries (151), and in LVH (24, 69).  
 
5.5 STRENGTHS AND LIMITATIONS 
All four studies in this thesis were retrospective, even though the data was acquired 
prospectively. This may introduce selection bias. However, the aim of Study I and Study II was 
to study carefully selected patients which we believe were unique and important strengths to 
investigate the hypotheses. Furthermore, all data except the Healthy volunteers and LVH-
Imaging cohorts in Study III was from a single university hospital in USA, and may not reflect 
a general global population. All ECG data was analyzed using the same dedicated semi-
automatic software, which may introduce a systematic bias, but a minimal interobserver 
variability. The A-ECG software is not optimal for analyzing certain heart arrhythmia including 
atrial fibrillation or abundant premature atrial or ventricular beats, rendering results that are not 
applicable to such patients. Furthermore, patients with bundle branch blocks were also 
excluded from all studies. 
In the studies investigating LVH and its electrocardiographic manifestations, only four 
conventional criteria were investigated, even though several have been recommended by the 
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American Heart Association. However, the most commonly used criteria in clinical routine 
were investigated, and sex-specific cut-offs were used. 
The increased LVMI and GTI scores in Study II, and ECG prognosis score and CMR prognosis 
score in Study IV were derived and validated in the same cohort. To account for this, the AUC 
was bootstrapped two thousand times to obtain confidence intervals. Even so, validation in 
separate cohorts is necessary. Nevertheless, nearly all ECG parameters incorporated into the 
scores have previously been shown to be associated with prognosis. In Study IV, the composite 
endpoint of hospitalization for heart failure and all-cause death was investigated, and all-cause 
death may not necessarily be due to cardiac disease. However, both endpoints are unfavorable, 
and all events of hospitalization for heart failure were based on strict criteria. The performance 
of the diagnostic and prognostic scores were evaluated by bootstrapping the cohort. The 
bootstrapped cohorts can only include features already present in the original cohort. Therefore, 
patients with other features than those present in the original cohort may not benefit from the 
same accuracy of the derived scores. 
 
5.6 CLINICAL PERSPECTIVES  
• The ECG is a common diagnostic tool and is used in many levels of the health care 
system. The studies in the current thesis give insight into the limited sensitivity of 
voltage-based ECG criteria for detecting increased LVM. This may be due to diffuse 
myocardial fibrosis, or due to the different patterns of LVH. However, wherever digital 
12-lead ECGs are available, the diagnostic scores from the studies could potentially be 
employed in the clinical software for improved diagnostics. Furthermore, the 
parameters in the newly proposed ECG prognosis score, namely the frontal QRS-T 
angle and QTc duration, are already available in clinical software, and thus the scores 
can easily be calculated in clinical routine. Patients with a high prognosis score may 
benefit from intensive risk management, surveillance, and possible therapeutic 
treatment, which warrants future prospective studies. 
 
• Electrocardiographic and anatomical properties of the heart are fundamentally different 
phenomena. We suggest that the term LVER should be used when discussing electrical 
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changes present in LVH. LVER, defined as an increased spatial QRS-T angle, was 
hardly present in healthy individuals, widely present in LVH, and present in patients 
with other cardiovascular pathologies also resulting in electrical remodeling. If a digital 
ECG analysis is not possible, LVER can be estimated manually from a paper-based 12-
lead ECG using established techniques (146), albeit probably with some compromise 
in accuracy and precision. Patients with LVER also had a poorer prognosis compared 
to those with no LVER, which warrants future studies on potential preventative 
treatments. 
 
• Both electrocardiographic, functional, and anatomical properties of the heart convey 
independent prognostic and diagnostic information. It is therefore beneficial to assess 
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6 CONCLUSIONS 
Conventional ECG has repeatably been shown to lack sensitivity for LVH. A-ECG can detect 
LVH with an improved accuracy. As LVH is an anatomical phenomenon and the ECG records 
electrical phenomena, the term LVER should preferentially be used when describing and 
diagnosing electrical changes commonly present in LVH. Lastly, the ECG carries added 
prognostic information beyond that of cardiovascular magnetic resonance imaging.  
The specific conclusions for each study were: 
I. Myocardial mass and diffuse myocardial fiborosis had independent and opposing 
effects upon ECG voltage measures of LVH. This provides mechanistic insight that 
could explain the limitied sensitivity of the ECG for detecting increased LVM. 
II. Increased LVM and GT, respectively, differed in their electrrocardiographical 
manifestation by A-ECG. New A-ECG scores outperform conventional ECG criteria 
for  LVH in determining increased LVMI and GTI. 
III. LVER rarely occurred in healthy volunteers, and was a mainstay of moderate or severe 
LVH. Furthermore, LVER was commoint evein in clinical patients without any LVH, 
and associated with outcomes. 
IV. An ECG prognosis score predicted outcomes independently of, and beyond, CMR. 
Combining the results of both an ECG and a CMR prognosis score, respectively, 
improved overall prognostic performance.  
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